3 posters to be published at 34th ECNP Congress

The 34th ECNP Congress will take place on October 2-5 in Lisbon. This is the most important European scientific meeting dedicated to brain research for disease. Each year, this event attracts over 5,000 psychiatrists, neurologists and psychologists from around the world. During the 34th ECNP Congress, posters will be presented. Posters by Sylwia Janowska –Read more »

Celon Pharma at EASD 2021

The EASD Annual Meeting is one of the largest scientific congresses, presenting the latest results from basic and clinical diabetes research and the place to meet the global diabetes community.

Celon Pharma Capital Markets Day – 21.04.2021

Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET / 16:00 Warsaw Time Zone. Join Corporate and KOL’s session. Prof. Eduard Vieta Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic and Prof. Jair C. Soares, MD, PhD –Read more »

Celon Pharma in the Stock Exchange Company of the Year ranking

Celon Pharma took 2nd place in the Development prospects category in the 22nd edition of the Stock Exchange Company of the Year 2020. The GSR report was prepared on the basis of an assessment of companies in the course of a special online survey in which companies & nbsp; to be assessed in accordance withRead more »

Celon Pharma at Top Picks by Trigon Investor Conference

On January 21, 2021, representatives of the Company’s Management Board will take part in the Top Picks by Trigon conference. Celon Pharma was among 21 companies recommended by Trigon DM in 2021.

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting.  In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »